262 related articles for article (PubMed ID: 33767059)
21. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.
Reidy KJ; Hjorten R; Parekh RS
Curr Opin Pediatr; 2018 Apr; 30(2):252-259. PubMed ID: 29406442
[TBL] [Abstract][Full Text] [Related]
22. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
23. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.
Scales SJ; Gupta N; De Mazière AM; Posthuma G; Chiu CP; Pierce AA; Hötzel K; Tao J; Foreman O; Koukos G; Oltrabella F; Klumperman J; Lin W; Peterson AS
J Am Soc Nephrol; 2020 Sep; 31(9):2044-2064. PubMed ID: 32764142
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in Drosophila.
Gerstner L; Chen M; Kampf LL; Milosavljevic J; Lang K; Schneider R; Hildebrandt F; Helmstädter M; Walz G; Hermle T
Kidney Int; 2022 Jun; 101(6):1216-1231. PubMed ID: 35120995
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia hits APOL1 in the kidney.
Grampp S; Krüger R; Lauer V; Uebel S; Knaup KX; Naas J; Höffken V; Weide T; Schiffer M; Naas S; Schödel J
Kidney Int; 2023 Jul; 104(1):53-60. PubMed ID: 37098381
[TBL] [Abstract][Full Text] [Related]
26. The Cell Biology of APOL1.
O'Toole JF; Bruggeman LA; Madhavan S; Sedor JR
Semin Nephrol; 2017 Nov; 37(6):538-545. PubMed ID: 29110761
[TBL] [Abstract][Full Text] [Related]
27. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
[TBL] [Abstract][Full Text] [Related]
28. A Brief History of APOL1: A Gene Evolving.
Friedman DJ
Semin Nephrol; 2017 Nov; 37(6):508-513. PubMed ID: 29110757
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein L1 and Kidney Disease in African Americans.
Friedman DJ; Pollak MR
Trends Endocrinol Metab; 2016 Apr; 27(4):204-215. PubMed ID: 26947522
[TBL] [Abstract][Full Text] [Related]
30. DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.
Chun J; Riella CV; Chung H; Shah SS; Wang M; Magraner JM; Ribas GT; Ribas HT; Zhang JY; Alper SL; Friedman DJ; Pollak MR
J Am Soc Nephrol; 2022 May; 33(5):889-907. PubMed ID: 35232775
[TBL] [Abstract][Full Text] [Related]
31. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
32. The key role of NLRP3 and STING in APOL1-associated podocytopathy.
Wu J; Raman A; Coffey NJ; Sheng X; Wahba J; Seasock MJ; Ma Z; Beckerman P; Laczkó D; Palmer MB; Kopp JB; Kuo JJ; Pullen SS; Boustany-Kari CM; Linkermann A; Susztak K
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651582
[TBL] [Abstract][Full Text] [Related]
33. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein L1 and kidney transplantation.
Tedla FM; Yap E
Curr Opin Organ Transplant; 2019 Feb; 24(1):97-102. PubMed ID: 30507707
[TBL] [Abstract][Full Text] [Related]
35. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
Gupta N; Waas B; Austin D; De Mazière AM; Kujala P; Stockwell AD; Li T; Yaspan BL; Klumperman J; Scales SJ
Sci Rep; 2024 Feb; 14(1):3765. PubMed ID: 38355600
[TBL] [Abstract][Full Text] [Related]
36. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
[TBL] [Abstract][Full Text] [Related]
37. APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.
Kopp JB; Heymann J; Winkler CA
Semin Nephrol; 2017 Nov; 37(6):514-519. PubMed ID: 29110758
[TBL] [Abstract][Full Text] [Related]
38. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
[TBL] [Abstract][Full Text] [Related]
40. APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin.
Uzureau S; Lecordier L; Uzureau P; Hennig D; Graversen JH; Homblé F; Mfutu PE; Oliveira Arcolino F; Ramos AR; La Rovere RM; Luyten T; Vermeersch M; Tebabi P; Dieu M; Cuypers B; Deborggraeve S; Rabant M; Legendre C; Moestrup SK; Levtchenko E; Bultynck G; Erneux C; Pérez-Morga D; Pays E
Cell Rep; 2020 Mar; 30(11):3821-3836.e13. PubMed ID: 32187552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
